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Abstract
Background: Standardized chemotherapy used in cancer patients with severe kidney insufficiency is ineffective.
Although there are some pharmacokinetic studies on cyclophosphamide in kidney insufficiency patients, to the
best of our knowledge, the pharmacokinetics and safety of combination of cyclophosphamide and docetaxel as
postoperative chemotherapy in a patient with early stage breast cancer undergoing hemodialysis is unclear thus far.
Case Presentation: The patient received regular TC regimen (cyclophosphamide 600 mg/m2, docetaxel 75 mg/m2).
She underwent hemodialysis 48 h after chemotherapy. Blood samples at multiple time-points were collected for
determination of plasma levels of cyclophosphamide and docetaxel. Pharmacokinetic analyses indicated that
compared with the reference data, the in vivo half-life (66.96 h) and drug exposure (150 %) of cyclophosphamide
significantly increased; however, pharmacokinetic parameters of docetaxel was unaffected. Patient developed grade
I thrombocytopenia and grade III leukopenia without any other severe adverse reactions. In total, four cycles of
treatment were completed. After the chemotherapy, the patient received tamoxifen as endocrine therapy for one
and a half years. No recurrence was reported.
Conclusion: These results suggest that the standard TC regimen is mostly safe and could be used as postoperative
adjuvant chemotherapy for hemodialysis patients with early stage breast cancer.
Keywords: Cyclophosphamide, Docetaxel, Pharmacokinetics, Hemodialysis, Breast cancer
Background
Cancer patients with chronic kidney disease are not un-
common. These patients generally have a high mortality.
The mortality rate of a cancer patient increases by 22 %
when the estimated glomerular filtration rate (GFR) de-
creases to 10 mL/min/1.73 m2 [1, 2]. This finding can be
attributed to the fact that GFR reduction not only in-
duces severe kidney complications but also restricts
tumor treatment, thereby promoting tumor progression.
GFR reduction reduces drug excretion and thus en-
hances drug exposure. This phenomenon leads to in-
creased toxicity, particularly in patients with severe
kidney insufficiency (phase III and above). Thus, those
patients with chemotherapy indications would have few
treatment options. Therefore, cancer patients with kid-
ney insufficiency are subject to high risks of tumor re-
currence and metastasis. However, whether or not such
patients can receive standardized chemotherapy or
whether dose adjustments are required for these pa-
tients, particularly those with end-stage renal disease
(ESRD), remains unknown thus far.
In this study, a patient with mastocarcinoma accompan-
ied by ESRD received postoperative cyclophosphamide/
docetaxel (TC) regimen. The peripheral blood levels
of these two drugs were measured to evaluate their
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pharmacokinetics, efficacy, and safety in the patient. TC
(600 mg/m2 cyclophosphamide + 75 mg/m2 docetaxel) is a
treatment regimen recommended by the National Com-
prehensive Cancer Network Guide to Practice of Breast
Cancer 2014 ver 1 [3]. Up to 50 % to 70 % of cyclophos-
phamide is eliminated through the kidney within 48 h
with 32 % eliminated unchanged and 68 % eliminated as
metabolites. Docetaxel and its metabolites are eliminated
in feces (75 %) and urine (6 %) within 48 h after adminis-
tration [4, 5]. It is obvious that both cyclophosphamide
and docetaxel are influenced by kidney excretory function,
particularly cyclophosphamide. Elimination distribution
ratio is altered (e.g., improved stool excretion) when
chemotherapy drugs get blocked in the main drainage
channel. In addition, the plasma concentration of chemo-
therapy drugs is possibly inconsistent with the side effect
of treatment. Thus, the feasibility of using the TC regimen
as adjuvant chemotherapy in a hemodialysis patient with
early stage breast cancer warrants further investigation.
Case Presentation
Case description
A 48-year-old female patient underwent modified left
radical mastectomy, pT2N0M0, IIa stage. Pathological
examination revealed infiltrative duct carcinoma (Level II
according to WHO classification) that was estrogen
receptor-positive (ER+, 95 %), progesterone receptor-
positive (PR+, 85–90 %), C-erB2 (1+), and Ki-67 (+, 35 %).
The patient had uremia eight years ago. She received
conventional hemodialysis treatment for eight years
(hemodialysis every 48 h), and has produced no urine.
The patient was administered 3000 units of erythropoi-
etin (biw) for chronic kidney disease accompanied by
mild to moderate anemia. The patient was diagnosed
with hypertension eight years ago. She was taking one
pill of nifedipine (bid) and 12.5 mg of metoprolol (bid)
to manage her blood pressure.
The treatment protocol for the patient was approved
by the Ethics Committee of the First Affiliated Hospital,
School of Medicine, Zhejiang University, and written in-
formed consent was obtained from her.
Treatment and Hemodialysis
After the operation, the patient (body surface area, 1.50 m2)
received 113 mg of 75 mg/m2 TC docetaxel (ivgtt, day 1)
and 900 mg of 600 mg/m2 cyclophosphamide (ivgtt, day 1).
The drugs were administered 2 h after hemodialysis. Cyclo-
phosphamide was administered by intravenous drip infu-
sion over 60 min. Then, normal saline was administered for
10 min for catheter rinsing. Docetaxel was then adminis-
tered by intravenous drip infusion over 50 min. After 48 h,
the next hemodialysis was performed with Polyflux 14 L
(Corp Gambro, Germany). The UF coefficient in vitro
and membrane area were 10.0 ml/(h · mmHg) and 1.4 m2,
respectively. The duration of hemodialysis was 4 h. This
program was repeated every three weeks, for a total of
four cycles. White blood cell count, blood platelet count,
hemoglobin count, liver and kidney functions, and other
indicators were regularly monitored during the treatment
process. When grade III neutropenia occurred, short-term
granulocyte colony stimulating factor (GCSF) was admin-
istered to support the treatment.
Pharmacokinetic analysis
We investigated the pharmacokinetics of docetaxel and
cyclophosphamide. A 5-mL aliquot of peripheral blood
was collected before administration of the regimen, 0.5,
1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 h after cyclophospha-
mide treatment, and 2 h after hemodialysis. The blood
was stored at 4 °C by using EDTA as an anticoagulant.
Then, the blood was centrifuged at 8000 rpm for
10 min. Plasma was stored at −80 C for later analyses.
Agilent 6460 Triple quadrupole liquid chromatography-
mass spectrometer (LC-MS/MS) (Agilent, Palo Alto,
CA) was used as previously described [6, 7] to measure
the plasma concentrations of cyclophosphamide and do-
cetaxel. The linear correlation coefficient (r2), limit of
detection, and limit of quantitation for cyclophosphamide
were 0.994, 0.5 μg/mL, and 1.5 μg/mL, respectively,
whereas those for doectaxel were 0.994, 0.1 ng/mL, and
0.5 ng/mL, respectively.
The data were analyzed using descriptive PK methods
by employing Kinetica version 5.0 (ThermoFisher Scien-
tific, CO, USA). The PK parameters of cyclophosphamide
and docetaxel were estimated using non-compartmental
method and standard two-compartmental method based
on the plasma concentrations excluding the post-dialysis
sample, respectively, and compared with the data reported
in the literature from patients with normal kidney function
(for cyclophosphamide, compared with literature [8, 9], for
docetaxel, compared with literature [10], [11], and [12]).
Results
The pharmacological characteristics of the patient ad-
ministered cyclophosphamide and docetaxel are shown
in Fig. 1, Fig. 2, and Table 1. The maximum plasma con-
centration of cyclophosphamide was 48.97 μg/mL. After
non-compartmental model fitting, the area under the
curve (AUC0~∞) was 3128 μg · h/mL and the in vivo
half-life was 66.96 h (Fig. 1 and Table 1). These values
were 1.5- and 11-fold higher than the typical values of
the reference group, respectively. The two-compartment
model was the best-fit model of docetaxel pharmaco-
kinetics. The highest plasma concentration, AUC0~∞,
and in vivo half-life of decetaxel were 65.85 ng/mL,
4430 ng · h/mL, and 21.53 h, respectively; these
values were similar to the typical values of the reference
group (Fig. 2 and Table 1). After hemodialysis, the plasma
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concentrations of cyclophosphamide and docetaxel de-
creased by 1.25 μg/mL (6.9 %) and 0.11 ng/mL (2.9 %),
respectively.
Four cycles of treatment were smoothly completed.
The patient developed grade I thrombocytopenia and
grade III leucopenia (classified according to NCI Com-
mon Terminology Criteria for Adverse Events Version 4)
after chemotherapy. These conditions improved after
administering suitable treatments. A previous study re-
ported that the incidence rates of grade III leukopenia
and grade I thrombocytopenia are approximately 10 %
and 1 %, respectively, when the TC regimen is used for
breast cancer [13]. After chemotherapy, the patient re-
ceived tamoxifen as endocrine therapy for one and a half
years. No recurrence was reported.
Conclusions
Kidney insufficiency affects the accumulation of drugs in
the body, increases drug exposure, and causes treatment
safety issues. Therefore, clinicians take extra cautions
when treating cancer patients with moderate to severe
kidney insufficiency. Discontinuation of chemotherapy
owing to increased side effects decreases the therapeutic
effect of a regimen.
This study attempted to use conventional TC regimen
as adjuvant chemotherapy to treat a hemodialysis patient
with early stage breast cancer. Exposure to cyclophos-
phamide significantly increased whereas the pharmaco-
kinetics of docetaxel remained unchanged in this
patient. Mild hematologic toxicity was observed in the
patient without severe non-hematologic toxicity. The pa-
tient received four cycles of treatments. No tumor recur-
rence and metastasis have been reported yet (i.e., after a
two-year follow-up period). These data suggest that ad-
juvant chemotherapy with the standardized dosages of
cyclophosphamide and docetaxel is safe and effective
when administered postoperatively to breast cancer pa-
tients with severe kidney insufficiency.
Several studies of the pharmacokinetics of cyclophos-
phamide in kidney insufficiency patients have already
been reported. Haubitz et al. [14] found that cyclophos-
phamide exposure increased as the severity of kidney
damage increased; for example, the cyclophosphamide
exposure increased by 1.2-fold in patients with phase V
kidney damage. Ekhart et al. [15] investigated the phar-
macokinetic changes of cyclophosphamide in patients
with moderate kidney insufficiency. They found that the
67 % increase in cyclophosphamide exposure might be not
sufficient to adjust the dosage. However, the changes in the
pharmacokinetics of cyclophosphamide in hemodialysis pa-
tients remain unclear thus far. In the present study, al-
though drug exposure significantly increased (150 %), the
standard dosage of cyclophosphamide was still found to be
relatively safe for the mastectomy patient with ESRD. In
fact, 1000 mg of cyclophosphamide as an imperative treat-
ment can still be highly tolerated by patients with im-
mune diseases, including lupus nephritis and chronic
kidney disease [16]. This finding may partially explain
the tolerance to high cyclophosphamide concentrations
observed in this study.
Docetaxel is not usually administered to patients with
renal insufficiency because of its low excretion rate via
Fig. 2 The serum concentration-time curves of docetaxel
Table 1 Pharmacokinetic parameters of the analyzed patient
and reported data of patients with normal kidney function
Compound Unit Patient Reference Deviation (%)
Cyclophosphamide
Cmax μg/mL 48.97 61.32 21.2 %
t1/2 hour 66.96 4 ~ 6 1016 %
AUC0~∞ μg · h/mL 3128 1917 56 %
Docetaxel
Cmax ng/mL 1132.6 1309 ~ 2930 13.6 ~ 61.4 %
t1/2 hour 21.53 7.8 ~ 21.0 2.5 ~ 176 %
AUC0~∞ ng · h/mL 4430 1990 ~ 3770 17 ~ 122 %
Fig. 1 The serum concentration-time curves of cyclophosphamide
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the kidneys. Dimopoulos et al. [17] investigated the ef-
fects of docetaxel in patients with urinary tract tumors
and late-stage kidney damage. They found that the toxic
effects of docetaxel slightly increased in patients with
kidney damage. However, the study did not investigate
the pharmacokinetic characteristics of docetaxel. The
present study showed that the pharmacokinetic parame-
ters of docetaxel remained unaffected and were compar-
able to those in the reference group, thereby meeting the
two-compartment model. Doxetaxel exposure slightly
increased, but no relative toxic effects on the patient
were observed. Similarly, postoperative breast cancer pa-
tients with ESRD can adapt to the normal dosage of
docetaxel.
Another interesting finding in our study is that
hemodialysis did not significantly influence the clearance
of cyclophosphamide and docetaxel. There are a few case
reports on pharmacokinetics of cyclophosphamide and
docetaxel in patients undergoing hemodialysis. Haubitz M
et al. [14] studied the effects of hemodialysis on the
pharmacokinetics of cyclophosphamide, and proved that
the plasma concentration of cyclophosphamide decreased
by 10 % after hemodialysis, while Hochegger K et al. [18]
revealed that following hemodialysis, the concentration of
docetaxel decreased by nearly 92 %. However, in this
study, the plasma concentrations of cyclophosphamide
and docetaxel decreased by only 6.9 % and 2.9 % after
hemodialysis, respectively, probably owing to individual
variability of cyclophosphamide clearance and low con-
centration of docetaxel in plasma at 48 h that led to lim-
ited elimination by hemodialysis. Therefore, we speculate
that the decreased drug toxicity was not attributed to
hemodialysis. However, the white blood cell count of the
patient increased to 40.5 × 109/L during the treatment
process. This result is attributable to the application of
GCSF. As a macromolecular protein with a molecular
weight of approximately 20000, GCSF will accumulate in
the body because it cannot be completely eliminated by
hemodialysis in the present study. The conventional dos-
age of short-term GCSF might markedly increase white
blood cell and neutrophilic granulocyte count. The white
cell count of the patient gradually normalized upon dis-
continuation of GCSF for 1 week. Therefore, the dosage
and frequency of GCSF should be adjusted accordingly in
hemodialysis patients.
This study has two limitations. First, we did not meas-
ure the metabolites of cyclophosphamide and docetaxel
owing to unavailability of the standard metabolites re-
quired for such analysis, which might explain the lack of
published data on such metabolites. Ekhart C et al. dem-
onstrated that the active metabolites of cyclophospha-
mide were not significantly affected in conditions of
renal impairment, similar to the condition described in
the present study [6]. Second, the generalizability of the
case still needs to be verified. Despite these limitations,
this study is the first to present the pharmacokinetic
data of cyclophosphamide and docetaxel in a breast can-
cer patient with ESRD. Overall, the TC regimen is prob-
ably safe and could be used for similar cases.
Consent
Written informed consent was obtained from the patient
for publication of this case report. A copy of the written
consent is available for review by the editor of this
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